C hronic kidney disease (CKD) has traditionally been considered to be an irreversible process, and patients who have it are often expected to experience a progressively worsening course. The rate of disease progression varies with the cause, and various therapeutic interventions, such as control of hypertension and proteinuria, have been shown to decrease it.
Hyperuricemia has been associated with adverse outcomes in CKD. Hyperuricemia has been linked to macrovascular heart disease in diabetic CKD. 1 High uric acid levels have been reported to be associated with increased rates of decline in glomerular filtration rate (GFR) in cross-sectional studies. 2, 3 Febuxostat is a xanthine oxidase inhibitor shown to be efficacious in hyperuricemia and gout. 4 It does not require dose modification in patients with kidney failure. Therapy with febuxostat has been shown to prevent renal damage in 5/6 nephrectomized rats. 5 The xanthine reductase inhibitor allopurinol has been shown to be effective in reducing lipid accumulation and atherosclerosis in apolipoprotein E (ApoE) knockout mice. 6 One randomized controlled trial has demonstrated the efficacy of allopurinol in reducing the rate of decline in GFR in patients with CKD with estimated GFRs (eGFRs) , 60 mL/min/ 1.73 m 2 . 7 In this context, we hypothesized that febuxostat might retard the progression of kidney disease in patients with CKD and hyperuricemia.
The aims of the study were to determine the efficacy of febuxostat compared to placebo for slowing eGFR decline in patients with CKD stages 3 and 4 (eGFR, 15-60 mL/min/1.73 m 2 ) and asymptomatic hyperuricemia (uric acid $ 7 mg/dL) and to compare the incidence of adverse cardiovascular events (myocardial infarction, cerebrovascular events, and heart failure), death, and hospitalization rates between the 2 groups. We also planned to compare treatmentassociated emergent adverse events between the febuxostat and placebo groups and evaluate the reduction in serum uric acid levels in both groups.
METHODS
This was a single-center, double-blind, randomized, parallelgroup, placebo-controlled study conducted in Eastern India. The study was approved by the IPGMER Research Oversight Committee (approval number Inst/IEC/1305). The participants gave written informed consent in accordance with the principles of the Declaration of Helsinki.
Eligible participants were patients of both sexes aged 18 to 65 years with eGFRs of 15 to 60 mL/min/1.73 m 2 (as calculated with the 4-variable MDRD [Modification of Diet in Renal Disease] Study equation). All had serum uric acid levels $ 7 mg/dL. Exclusion criteria were requirement of medication (excluding diuretics) or conditions that may increase uric acid levels, such as disorders of primary uric acid metabolism. Patients with autosomal dominant polycystic kidney disease were also excluded, 8 as well as those with pregnancy, lactation, and symptomatic hyperuricemia or gout.
The study was carried out in a government tertiary-care center in Kolkata, in Eastern India. This is a primary referral center for kidney disease from West Bengal. Total study duration was 18 months; patients were recruited from February 2012 through January 2013 and follow-up of the last patient ended in July 2013.
Patients randomly assigned to the study drug febuxostat received 40-mg tablets to be taken once daily after breakfast. Patients randomly assigned to placebo received tablets to be taken at the same time. Both groups received antihypertensive medication, including angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, unless there was a specific contraindication. Diuretics were administered as clinically indicated. Drugs and placebo were continued throughout the study period. Patients were evaluated at baseline and every 3 months for history, physical examination, assessment of any adverse events or end points, serum creatinine levels, uric acid levels, urine examination, and any other tests as needed by the treating clinician. Every patient had at least 3 serum creatinine measurements over the 6-month period. The intervention period and follow-up duration were at least 6 months for each patient.
The primary outcome was the proportion of patients showing a $10% decline in eGFR from baseline in the febuxostat and placebo populations. 9 Secondary outcome measures were changes in eGFR in the 2 groups from baseline and at the end of the study period, cardiovascular events (myocardial infarction, stroke, or heart failure), death due to any cause, development of CKD stage 5 (eGFR decrease to ,15 mL/min/1.73 m 2 ), changes in uric acid levels in the 2 populations, and development of any drug-related adverse events. Cardiovascular events were defined by hospital admissions with the diagnosis being reached with appropriate clinical and laboratory criteria.
The proportion of patients with a $10% decline in eGFR between the febuxostat and placebo groups was used as the primary efficacy variable for sample-size calculation. If it is hypothesized that this rate is 25% in the placebo group with an effect size of 20%, we calculated that we would need to recruit 49 individuals in each group with an equal allocation ratio to be able to reject the null hypothesis with power of 80% and type I error probability of 0.05. We have used an uncorrected c 2 statistic to evaluate this null hypothesis. However, we proposed to recruit 54 individuals per group assuming a 10% dropout rate in order to achieve the desired sample size.
A computer-generated random-number table was used for allocation of individuals to the study drug and placebo in a 1:1 ratio.
Febuxostat and placebo were provided as white tablets identical in appearance and taste and were prepackaged in identical bottles. Allocation concealment was done by sealed sequentially numbered opaque envelopes. They were consecutively numbered and bottles were given out according to the number allocated to the participant. The investigator was blinded to the allotment as the procedure was carried out by a third person.
A modified intention-to-treat analysis was performed for efficacy and safety data. Individuals who attended the baseline and at least 2 postbaseline follow-up visits were considered for analysis. Summary statistics of numeric variables were expressed as mean 6 standard deviation, and categorical data, as proportion. Baseline variables were compared between groups to detect any variability at baseline. To determine differences between groups of categorical data (eg, proportion with $10% decline in eGFR or proportion with cardiovascular adverse events), Fisher exact test or Pearson c 2 test were used as applicable. Between-group comparison of numeric parametric data was done by unpaired t test. Within-group repeated-measure parametric data were compared for statistical significance using repeated-measure analysis of variance. The 95% confidence interval (CI) of the difference between mean values was determined and P , 0.05 was considered statistically significant.
RESULTS
Two hundred five patients were screened for initial enrolment (Fig 1) visits and were available for analysis. Two individuals from the febuxostat group and 3 from the placebo group had dropped out before completing the study, but were included in the modified intention-to-treat analysis.
Patients were recruited from February 2012 through January 2013 and follow-up of the last patient ended in July 2013. Baseline characteristics of patients are presented in Table 1 . There were no significant differences in the febuxostat and placebo groups with respect to baseline variables, apart from uric acid level, which was higher in the febuxostat group at baseline. Torsemide, telmisartan, and amlodipine were the drugs most commonly used as loop diuretics and antihypertensives, respectively. Average blood pressure in the febuxostat group was 149.5/85.4 mm Hg, which decreased to 136.6/80.0 mm Hg at 6 months. Average blood pressure in the placebo group was 138.5/ 80.5 mm Hg at baseline and decreased to 134.4/ 82.9 mm Hg at 6 months.
Changes in eGFRs in the febuxostat and placebo groups over 6 months are presented in Table 2 . Mean eGFR in the febuxostat group showed a nonsignificant increase from 31.5 6 13.6 (standard deviation) at baseline to 33.7 6 16.6 mL/min/1.73 m 2 at 6 months. In the placebo group, mean eGFR decreased from 32.6 6 11.6 to 28.2 6 11.5 mL/min/1.73 m 2 over the same period, and this decrease was statistically significant (P 5 0.003). The between-group difference in eGFRs was significant at 6 months (6.5 [95% CI, 0.1-12.8] mL/ min/1.73 m 2 ; P , 0.05). Mean changes in eGFRs were 13.2 and 24.4 mL/min/1.73 m 2 in the febuxostat and placebo groups, respectively. In the febuxostat group, 17 of 45 (38%) participants had a $10% decrease in eGFR over baseline compared with 26 of 48 (54%) participants in the placebo group. This difference was statistically significant (P , 0.004; Table 3 ).
Changes in serum uric acid levels are presented in Table 4 . Febuxostat consistently decreased serum uric acid levels by w40% from baseline. The placebo group also had a smaller decrease in uric acid levels, which may be due to dietary modification after nutritional counseling. Mean changes in uric acid levels were 23.8 and 20.5 mg/dL in the febuxostat and placebo groups, respectively, from baseline to 6 months. Adverse events that could be directly attributed to the drug were very few; only 2 patients had mild diarrhea, both in the febuxostat group, while none in the placebo group had adverse reactions. Neither of these 2 patients required discontinuation of therapy. Fifteen of 45 patients in the febuxostat group and 28 of 48 patients in the placebo group had ischemic heart disease. However, no patient had a cardiovascular event during the trial period, and Abbreviations: ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration rate. there were no deaths in either group. Six patients in the febuxostat group and 4 patients in the placebo group reached eGFRs , 15 mL/min/1.73 m 2 during the study period. None of them required dialysis.
Adherence to the protocol was assessed by inspecting the empty containers for the drugs. Two patients each from the febuxostat and placebo groups had ,90% adherence with respect to the drug prescribed.
DISCUSSION
The present study demonstrates that febuxostat, when given to hyperuricemic patients with CKD, decreases hyperuricemia and slows eGFR decline. The therapy was well tolerated and safe.
There are several indications that the development and progression of CKD are inextricably linked with uric acid level. Epidemiologic data from a Korean population showed that asymptomatic men with hyperuricemia had greater odds of developing CKD than normouricemic men (odds ratio, 1.96). 10 Hyperuricemia was shown to be an independent risk factor for new-onset microalbuminuria in a middle-aged and elderly Taiwanese population. 11 In a Japanese cohort, hyperuricemia was reported to be an independent risk factor for decrease in eGFR. 12 In a cohort of patients with type 2 diabetes without overt proteinuria, hyperuricemia was found to be associated with the development of CKD. 13 Hyperuricemia has also been linked to contrast-induced acute kidney injury, 14 associated with the prevalence of left ventricular hypertrophy and progression to dialysis dependence, 15 and described as a risk factor for mortality in patients with CKD who underwent coronary intervention 16 and as a risk factor for increased all-cause mortality in peritoneal dialysis patients. 17 A Taiwanese study showed that higher uric acid levels are associated with increased creatinine levels, and individuals with serum uric acid levels . 6 mg/dL were reported to have greater decreases in kidney function. 18 However, in an analysis of the MDRD Study population, the highest uric acid level tertile did not lead to an increased incidence of CKD. 19 Lowering uric acid levels may decrease disease progression in patients with CKD. In a trial of 96 patients randomly assigned to an allopurinol or control group, those who were prescribed allopurinol had lower serum uric acid levels, and in those patients, mean GFR increased 3.3 6 1.2 mL/min/1.73 m 2 per year, whereas it decreased 1.3 6 0.6 mL/min/1.73 m 2 in the control group during follow-up (P 5 0.04). 20 Febuxostat has been used in patients with gout, and in the Febuxostat/Allopurinol Comparative Extension Long-term (EXCEL) Study, use of febuxostat was shown to preserve kidney function. Greater continued reductions in serum uric acid levels were reported to be associated with less decline in kidney function (P , 0.001) by statistical modeling. The data indicated that for every 1-mg/dL of long-term reduction in serum uric acid level in persons with gout, 1.2 mL/ min/1.73 m 2 of eGFR would be preserved. 21 In a study of 6,400 individuals with normal kidney function, after adjustment for other risk factors, serum uric acid level . 8.0 versus ,5.0 mg/dL was found to be associated with a subsequent increased risk for kidney failure within 2 years (2.9-fold in men and 10.0-fold in women). 22 In another prospective study, lowering uric acid levels in hyperuricemic patients with normal kidney function was observed to improve GFRs. 23 Hyperuricemia may cause activation of the reninangiotensin system. Hyperuricemia acts both directly (by reducing neuronal nitric oxide synthesis in the juxtaglomerular apparatus) and indirectly (by reduced kidney perfusion consecutive to afferent arteriolar vascular smooth cell proliferation or by the induction of cyclooxygenase 2 in the macula densa and arterioles). A decrease in neuronal nitric oxide synthase in the macula densa and an increase in juxtaglomerular renin release has been described; this injury is attenuated by enalapril and L-arginine, suggesting that damage occurs by a crystal-independent mechanism by activation of the renin-angiotensin system and decrease in nitric oxide synthases. 24, 25 Animal models (predominantly using a uricase inhibitor, oxonic acid) demonstrate that hyperuricemia brings about arteriolopathy of preglomerular vessels, which negatively affects the autoregulatory response of afferent arterioles, resulting in glomerular hypertension. Vascular wall thickening occurs, causing lumen obliteration and severe kidney hypoperfusion; the ischemia that then occurs is a powerful stimulus by which tubulointerstitial inflammation and fibrosis, as well as arterial hypertension, are induced. 26 Hyperuricemic rats thus show kidney injury, tubulointerstitial fibrosis, glomerular hypertrophy, and glomerulosclerosis; however, control of uric acid levels with allopurinol prevents development of these renal changes. 27 In adenine-fed rats, levels of markers of inflammation (TNF-a), fibrosis (TGF-b), and oxidative stress (heme oxygenase 1) increase along with kidney fibrosis, and allopurinol reverses these changes. 28 In a 5/6 nephrectomized rat model, hyperuricemic rats given oxonic acid have been reported to show more severe kidney failure, proteinuria, and histologic changes compared with normouricemic rats. Increased cyclooxygenase 2 expression in hyperuricemia has been associated with proliferation of vascular smooth muscle cells in preglomerular arteries. 29 Experimental evidence also links hyperuricemia and exacerbation of kidney injury caused by diabetes. In diabetic (db/db) mice that developed hyperuricemia and kidney disease, allopurinol has been reported to reduce albuminuria and decrease tubulointerstitial injury. This is mediated by a reduction in inflammatory cells due to reduction in intercellular adhesion molecule 1 expression by tubular epithelial cells. 30 The major limitations of the present study include small sample size and short duration of follow-up. The number of patients in the trial may have been insufficient to assess safety. Thus, the findings need to be corroborated over a larger sample size and longer duration. We did not assess proteinuria and hypertension for the purposes of the study, although angiotensin receptor blockers were used in patients preferentially unless contraindicated and additional drugs were used to achieve JNC 8 (Eighth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure) goals. Participants were drawn from a relatively homogeneous population of Eastern India, and the applicability of the findings to other races or populations is unknown. For instance, the average normal protein intake of the study population was 0.6 g/kg. However, studies of other population groups with allopurinol have shown a similar result. 16, 17 In conclusion, this single-center, double-blind, randomized, parallel-group, placebo-controlled study showed that febuxostat slowed the decline in eGFR in individuals with CKD stages 3 and 4 and asymptomatic hyperuricemia compared to placebo.
